34 Deaths, 302 Serious Injuries: RSV Vaccines Aren’t Even a Year Old but Some Experts Say It’s Time to Pull Them From the Market


by Michael Nevradakis, Ph.D., Childrens Health Defense:

Newly approved vaccines for respiratory syncytial virus have been linked to deaths and serious injuries and, most recently, to Guillain-Barré syndrome, but U.S. health officials continue to recommend them as “safe and effective.”

It’s been less than a year since the Centers for Disease Control and Prevention (CDC) recommended two new respiratory syncytial virus (RSV) vaccines — yet CDC data and the Vaccine Adverse Event Reporting System (VAERS) already show reports of 34 deaths, 302 serious adverse events and according to news reports this week, a safety signal for Guillain-Barré syndrome (GBS).

TRUTH LIVES on at https://sgtreport.tv/

Reported cases include several instances of severe adverse events in newborns, including the death of a 27-day-old baby who was wrongly administered the vaccine, and in pregnant women and people in age groups for which the RSV vaccines were not approved.

The U.S. Food and Drug Administration (FDA) approved Pfizer’s Abrysvo and GSK’s Arexvy RSV vaccines for adults ages 60 and older — but not for children or babies.

Abrysvo is also approved for pregnant women, targeting RSV prevention in babies. The FDA approved Abrysvo and Arexvy in May 2023.

According to CDC data, approximately 9.65 million RSV vaccine doses — 6.58 million Arexvy doses and 3.06 million Abrysvo doses — were administered as of Feb. 16.

Members of the CDC’s Advisory Committee on Immunization Practices (ACIP) presented the data on deaths and adverse events related to the RSV vaccines at a Feb. 29 meeting.

Yet, ACIP — and news media reports — primarily focused on GBS safety signals, glossing over deaths and the administration of the vaccines to unauthorized age groups.

Instead, CDC officials claimed it’s too early to determine if the RSV vaccines caused the adverse events and reiterated that the shots are safe, according to The Associated Press (AP).

Experts who spoke with The Defender disputed the CDC’s reassurances. Brian Hooker, Ph.D., chief scientific officer for Children’s Health Defense (CHD), said “34 deaths in 10 months should be sufficient to pull the RSV vaccines from the market. But the FDA will not do that — nor will there be full investigations regarding these deaths.”

“I am greatly concerned with the excessive application of the RSV vaccine,” said cardiologist Dr. Peter McCullough. “We are beginning to see the tip of the iceberg in terms of serious side effects.”

Syring into Vials

CDC creating ‘illusion of safe and effective’

According to the CDC data presented at the Feb. 29 ACIP meeting, of the 34 deaths reported as of Feb. 16 following RSV vaccination, 22 were linked to Arexvy and nine to Abrysvo. In three instances, the report listed “no brand name.”

Yet, discrepancies in the data are evident, as the public-facing VAERS database indicates only 29 RSV vaccine-related deaths as of Feb. 23. And according to Albert Benavides, founder of VAERSAware.com, three more “hidden” deaths reported after RSV vaccines are listed in VAERS, but the vaccine name is unlabeled.

Benavides, who identified discrepancies and contradictions in VAERS data and has called attention to the existence of two parallel VAERS databases — one that is public-facing and one that is not — said, “It is simply gross and despicable the CDC and FDA are allowed to pass off this data obfuscation as pharmacovigilance.”

He added: “VAERS administration is simply not publishing all legitimate reports received.”

One of the deaths recorded in VAERS involved a 27-day-old baby from New York — even though the RSV vaccines are not approved for children. According to the report, which was entered into the VAERS database on Jan. 8, the newborn was vaccinated at a doctor’s office “and he passed away right there.” The date of death was unspecified.

Other RSV vaccine-related death reports included:

  • report involving a foreign woman of “unknown” age but who was pregnant. She received Abrysvo Dec. 27, 2023, and died Jan. 1, 2024.
  • 67-year-old New Jersey man who received Arexvy Oct. 14, 2023, and died two days later — a death acknowledged by GSK as “related to Arexvy.”
  • 69-year-old Florida man who received Arexvy concurrently with the Pfizer COVID-19 vaccine Sept. 28, 2023, and died two days later. According to the VAERS report, an EKG on the date of his death was “grossly ‘abnormal’” despite no known cardiac history and an “unremarkable” cardiac exam two months prior.
  • 70-year-old California man who received Arexvy concurrently with a flu vaccine on Sept. 5, 2023. Increased coughing and fever began “less than 24 hours later” and lasted for four days, until “the patient was found deceased at home.”
  • 73-year-old Virginia male who received Arexvy Jan. 24 and was diagnosed with GBS. Symptoms began 11 days after vaccination. He died Feb. 15.
  • 75-year-old Virginia woman who received Arexvy Jan. 4, died two hours later.
  • 76-year-old Michigan man who received Arexvy Jan. 11, sustained tachycardia and difficulty breathing, and died of acute sepsis and pneumonia Jan. 15.
  • 77-year-old Pennsylvania man who received Arexvy Jan. 4 and soon experienced “seizure-like activity” despite no history of seizures. He died Jan. 6.
  • An 81-year-old California man who received Arexvy and a flu vaccine Sept. 18, 2023. He sustained severe cardiopulmonary arrest and died five hours later.
  • An 81-year-old New Mexico woman who received Arexvy concurrently with the Moderna COVID-19 vaccine, and pneumonia, adenovirus and flu vaccines, on Oct. 19, 2023. On Oct. 29, 2023, she sustained a hemorrhage and later died.
  • An 85-year-old Colorado man who received Abrysvo and a flu vaccine on Sept. 11, 2023. Two days later, he “developed symptoms of shingles in his eye” and later “developed meningitis/encephalitis that led to a host of other complications that ultimately led to his death” on Dec. 21, 2023.

According to Benavides, other deaths likely related to RSV vaccination are “hidden” within VAERS, with details such as the vaccine name listed as “unknown” in some reports.

Read More @ ChildrensHealthDefense.org